Ankylosing Spondylitis Market Insights, Epidemiology Facts, and Market Report 2032

The Ankylosing Spondylitis market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Ankylosing Spondylitis market. A detailed review of the historical and forecasted Ankylosing Spondylitis market is included in the report, covering drug outreach in the 7MM.


Ankylosing Spondylitis Overview

Ankylosing Spondylitis (AS) also called Bechterew’s disease is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. Clinical features of this group include inflammatory back pain, asymmetrical peripheral oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. AS affects men more often than women.


Get Access to a Free Copy of Our Latest Sample Report @


Some of the key highlights of the Ankylosing Spondylitis Market Report

DelveInsight’s estimates suggest that there were 1,389,116 prevalent cases of AS in 2017 in the 7MM, and these prevalent cases are expected to increase further during the study period, 2017–2030.
As per DelveInsight’s assessments, the United States accounted for the highest prevalent population of Ankylosing Spondylitis, followed by EU5 and Japan.
AS is typically diagnosed in people younger than 40 years, and about 80% of patients develop first symptoms when they were younger than 30 years. Less than 5% of patients present when they are older than 45 years (Wenker et al., 2019).
According to the review of literature, the total prevalence of SpA in Germany is approximately 1–1.4% and the prevalence of AS is estimated to be 0.5% (Braun et al., 2019).


Ankylosing Spondylitis Epidemiology Segmentation

Total Prevalent Cases
Gender Specific Prevalent Cases
Diagnosed Cases
Severity-Specific Prevalent Cases


Ankylosing Spondylitis Treatment Market

Ankylosing Spondylitistreatment goals are alleviation of pain, recovery of physical functions related to daily life, occupational activities, and delay of structural damage responsible for physical impairments. The most important component of non-drug treatments of Ankylosing spondylitis (AS) is the education of patients and regular exercise.


Ankylosing Spondylitis Market Outlook

At present, the therapeutic market size of AS is mainly accounted for by physical therapy, surgery, non-steroidal anti-inflammatory drugs (NSAIDs: ibuprofen, and naproxen), steroids (corticosteroids), disease-modifying anti-rheumatic drugs (DMARDs: methotrexate), and biologics.


Download Free Sample Report Now @


Ankylosing Spondylitis Diagnosis

The most commonly used criteria for the classification of AS were developed in 1966 and modified in 1984. They are:

1. Low back pain of at least three months duration with inflammatory characteristics (improved by exercise, not relieved by rest)

2. Limitation of lumbar spine motion in sagittal and frontal planes

3. Decreased chest expansion (relative to normal values for age and sex)

4. Bilateral sacroiliitis grade 2 or higher

5. Unilateral sacroiliitis grade 3 or higher.


Ankylosing Spondylitis Treatment

Treatment of Ankylosing spondylitis will depend on the symptoms, age, and general health. It will also depend on how severe the condition is. The treatment goal is to reduce pain and stiffness, prevent deformities, and maintain as normal lifestyle as possible. Treatment may include: Nonsteroidal anti-inflammatory medications to reduce pain and inflammation, tumor-necrosis-factor blockers (biologic medications) to reduce inflammation and swelling, disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine to decrease inflammation and control AS, short-term use of corticosteroids to reduce inflammation, short-term use of muscle relaxants and pain relievers to relieve severe pain and muscle spasms, surgery to replace a joint, place rods in the spine, or remove parts of the thickened and hardened bone. Moreover, maintaining proper posture and regular exercise, including exercises that strengthen back muscles, is vital (Johns Hopkins Medicine, n.d.)


Ankylosing Spondylitis Emerging Drugs

Tofacitinib: Pfizer
Bimekizumab: UCB Biopharma


Download Free Sample Report Now @


Ankylosing Spondylitis Companies

UCB Inc.
Janssen Biotech
Iroko Pharmaceuticals
Biogen, and others


Ankylosing Spondylitis Drugs

Cimzia, and others


Table of content

1. Key Insights

2. Executive Summary

3. Disease Background and Overview

4. Case Reports

5. Patient Journey

6. Epidemiology and Patient Population

7. Current Treatment and Medical Practices

8. Unmet needs

9. Marketed drugs

10. Emerging Therapies

12. Potential of Emerging Therapies and Current therapies

13. Attribute Analysis

14. Key Market Forecast Assumptions

15. Market Methodology

16. Ankylosing Spondylitis (AS): United States Market Outlook

17. Market Drivers

18. Market Barriers

19. SWOT Analysis

20. Reimbursement and Market access

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight


Consult with our Business Expert @


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States